These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 7481784)
21. HIV/AIDS: vaccines and alternate strategies for treatment and prevention. Voronin Y; Phogat S Ann N Y Acad Sci; 2010 Sep; 1205 Suppl 1():E1-9. PubMed ID: 20860672 [TBL] [Abstract][Full Text] [Related]
22. Vaccine news from the 12th World AIDS Conference. Mirken B BETA; 1998 Oct; ():26-9. PubMed ID: 11365985 [TBL] [Abstract][Full Text] [Related]
24. Poxvirus vector-based HIV vaccines. Pantaleo G; Esteban M; Jacobs B; Tartaglia J Curr Opin HIV AIDS; 2010 Sep; 5(5):391-6. PubMed ID: 20978379 [TBL] [Abstract][Full Text] [Related]
25. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234 [TBL] [Abstract][Full Text] [Related]
26. [Development of HIV vaccines]. Shibata R Nihon Rinsho; 2002 Apr; 60(4):790-7. PubMed ID: 11968790 [TBL] [Abstract][Full Text] [Related]
27. The HIV vaccine paradox. Cohen J Science; 1994 May; 264(5162):1072-4. PubMed ID: 8178162 [No Abstract] [Full Text] [Related]
28. HIV. The modern era of HIV-1 vaccine development. Mascola JR Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931 [No Abstract] [Full Text] [Related]
29. What are the correlates of protection? Cohen J Science; 1993 May; 260(5112):1259. PubMed ID: 8493565 [No Abstract] [Full Text] [Related]
30. An anti-idiotype vaccine for AIDS based on the HIV receptor. Dalgleish AG Ann Ist Super Sanita; 1991; 27(1):27-31. PubMed ID: 1683525 [TBL] [Abstract][Full Text] [Related]
31. Vaccine drought spurs NIAID plan to improve industry ties.. Cohen J Science; 1996 Mar; 271(5253):1227-8. PubMed ID: 8638098 [No Abstract] [Full Text] [Related]
32. Human studies in the development of human immunodeficiency virus vaccines. Dolin R J Infect Dis; 1995 Nov; 172(5):1175-83. PubMed ID: 7594651 [TBL] [Abstract][Full Text] [Related]
33. US and Thai Governments defend HIV/AIDS vaccine trial in Thailand. Agnew B Bull World Health Organ; 2004 Mar; 82(3):231. PubMed ID: 15112014 [No Abstract] [Full Text] [Related]
34. Protection from HIV infection or AIDS? Miedema F; Meyaard L; Klein MR Science; 1993 Nov; 262(5136):1074-6. PubMed ID: 8235627 [No Abstract] [Full Text] [Related]
35. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy. Haynes BF; Yasutomi Y; Torres JV; Gardner MB; Langlios AJ; Bolognesi DP; Matthews TJ; Scearce RM; Jones DM; Moody MA Trans Assoc Am Physicians; 1993; 106():33-41. PubMed ID: 8036743 [No Abstract] [Full Text] [Related]
36. Disappointing data scuttle plans for large-scale AIDS vaccine trial. Cohen J Science; 2002 Mar; 295(5560):1616-7. PubMed ID: 11872804 [No Abstract] [Full Text] [Related]
37. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Bower JF; Green TD; Ross TM Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849 [TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees. Bagarazzi ML; Boyer JD; Javadian MA; Chattergoon M; Dang K; Kim G; Shah J; Wang B; Weiner DB J Med Primatol; 1997; 26(1-2):27-33. PubMed ID: 9271186 [TBL] [Abstract][Full Text] [Related]